Results 21 to 30 of about 49,935 (237)
, 2020 Objectives:In this study, we aimed to determine the clinical, laboratory and demographic characteristics of patients with rheumatoid arthritis (RA) using tofacitinib, and the drug survival rates.Materials and Methods:A total of 78 RA patients who were ...
Ayşe Bahar Keleşoğlu Dinçer +9 more
core +1 more source
Tofacitinib for treating severe alopecia areata: a case series
, 2022 Aims: To demonstrate the effectiveness and safety of oral tofacitinib in treating severe alopecia areata. Methods: We present a case series of four patients with severe alopecia areata treated with oral tofacitinib (Xeljanz) on compassionate supply ...
Sander, Christina, O'Bryen, John
core +1 more source
Possibilities for the use of tofacitinib in patients with COVID-19
Качественная клиническая практика, 2020 No published trials measuring effectiveness of tofacitinib in COVID-19 have been identified. Some professional associations recommend discontinuing tofacitinib if SARS-CoV-2 infections is detected.
A. V. Matveev +2 more
doaj +1 more source
Immuno, 2021 Entheseal spinal inflammation and new bone formation with progressive ankylosis may occur in ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
Tobias Russell +7 more
doaj +1 more source
Tofacitinib-induced eosinophilia � First case report [PDF]
, 2023 Tofacitinib is an oral small molecule JAK inhibitor approved for the treatment of moderate to severe ulcerative colitis (UC). Its efficacy and safety have been demonstrated in phase III clinical trials and supported by real-life data.
Ana Teresa Ferreira +15 more
core +1 more source
Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies [PDF]
Intestinal Research, 2018 Background/AimsTofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo or tofacitinib 10 mg twice daily ...
Satoshi Motoya +10 more
doaj +1 more source
Scientific Reports, 2023 We aimed to determine the risk of herpes zoster (HZ) in Korean rheumatoid arthritis (RA) patients on tofacitinib compared with tumor necrosis factor inhibitor (TNFi) treatment.
Yeo-Jin Song +12 more
doaj +1 more source
Tofacitinib Decreases Autophagy of Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients
Frontiers in Pharmacology, 2022 The pathway of Janus tyrosine kinases (JAKs) has a central role in the pathogenesis of Rheumatoid Arthritis (RA) by regulating multiple immune functions and cytokine production.
M. Vomero +16 more
doaj +1 more source
Journal of International Medical Research, 2019 Background Tofacitinib is an oral Janus kinase (JAK) inhibitor that targets JAK1 and JAK3, and thus regulates immune response. Therefore, tofacitinib is used to treat immune-mediated inflammatory diseases such as chronic plaque psoriasis.
Fangyuan Tian, Zhaoyan Chen, Ting Xu
doaj +1 more source
Ulcerative colitis: short-term efficacy and safety of tofacitinib
, 2023 reservedTofacitinib è indicato per pazienti adulti affetti da retto colite ulcerosa moderata-grave che hanno manifestato una risposta inadeguata o hanno perso la risposta o che sono risultati intolleranti alla terapia convenzionale o a un agente ...
BELOTTI, MARTA
core